ArticleIJU case reports2024
Severe neutropenia caused by palliative radiation therapy in a case of metastatic hormone-sensitive prostate cancer.
Article in IJU case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Radiotherapy for widespread bone metastasis results in severe hematological toxicity. Case presentation: A 71-year-old male was diagnosed with metastatic hormone-sensitive prostate cancer (cT4N1M1b) and treated with apalutamide and degarelix. Concurrently, palliative radiation therapy was sequentially initiated for the 1st, 5th, and 10th thoracic vertebrae and right femur. On day 35 after treatment, severe neutropenia necessitated treatment interruption and required 23 days for neutrophil recovery with a granulocyte colony-stimulating factor agent. Conclusion: Owing to the severe hematologic toxicity caused by extensive radiation therapy for multiple bone lesions, treatment prioritization by lesion and avoiding irradiation of the red bone marrow is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.